CD274 and hepatocellular carcinoma: The present multicenter, retrospective, matched cohort study (CHANCE001) based on the nationwide data showed that TACE with PD-(L)1 inhibitors plus MTT significantly improved PFS, OS, and ORR in predominantly advanced HCC patients when compared to TACE alone.